Phase 3, Randomized, Open-label, Controlled, Multiple Dose, Efficacy, Safety, Pharmacokinetic, and Pharmacodynamic Study of Etelcalcetide in Pediatric Subjects 28 Days to < 18 Years of Age With Secondary Hyperparathyroidism and Chronic Kidney Disease Receiving Maintenance Hemodialysis
Amgen
Summary
This is a phase 3 trial of etelcalcetide in pediatric participants with secondary hyperparathyroidism (SHPT) and chronic kidney disease (CKD) on hemodialysis.
Description
SHPT is a common and serious co-morbidity that develops relatively early in the course of CKD, worsens with declining kidney function, and is associated with serious complications in children on dialysis. Children on dialysis experience a wide spectrum of bone abnormalities and growth retardation, in addition to increased risk for cardiovascular morbidity and mortality that manifests early in their adulthood. Traditional therapies for SHPT (eg, vitamin D sterols) are widely used in the pediatric dialysis population, and have the potential to aggravate complications of the disease by increasing…
Eligibility
- Age range
- 0–18 years
- Sex
- All
- Healthy volunteers
- No
Inclusion criteria * Age of 28 days \< 18 years. * Dry weight ≥ 7 kg during screening. * Diagnosed with CKD and SHPT undergoing hemodialysis at the time of screening. * Diagnosis of SHPT with the mean of the 2 consecutive central laboratory iPTH values ≥ 300 pg/mL (32 pmol/L) during screening, on separate days and within 2 weeks of enrolment. * Serum corrected calcium (cCa) value ≥ 9.0 mg/dL (2.25 mmol/L) for participants ≥ 2 years of age and older and serum cCa value ≥ 9.6 mg/dL (2.4 mmol/L) for participants 28 days to \< 2 years of age obtained from the central laboratory during screening.…
Interventions
- DrugEtelcalcetide
Etelcalcetide has been shown to be safe and efficacious in treating adult CKD patients with SHPT by simultaneously controlling iPTH, Ca, and phosphorus and has recently been approved for use in adult patients with SHPT treated with hemodialysis in both the United States and Europe
- OtherStandard of Care
Standard of care, which can include therapy with vitamin D sterols, Ca supplementation, and/or phosphate binders
Locations (43)
- Childrens Hospital of Los AngelesLos Angeles, California
- Childrens Hospital ColoradoAurora, Colorado
- Childrens Mercy HospitalKansas City, Missouri
- Mount Sinai Kidney Center - B1 Renal TreatmentNew York, New York
- Cincinnati Childrens Hospital Medical CenterCincinnati, Ohio
- Cleveland Clinic FoundationCleveland, Ohio